The second relationship was not completely new and has already been raised by another group that have shown a significant correlation between the frequency of CD56+CD16+ effector lymphocytes among PBMCs and ADCC induced by in vitro addition of trastuzumab in patients with operable breast cancer overexpressing HER2, before and after therapy with trastuzumab (70). This evidence concerns the gene ERBB2 and breast cancer.